Docaravimab,Miromavimab

Docaravimab and Miromavimab are two monoclonal antibodies used together as a rabies monoclonal antibody cocktail for post-exposure prophylaxis following suspected exposure to rabies virus. They are immunoglobulin-based antiviral biologics that provide passive immunity by binding to different antigenic sites on the rabies virus glycoprotein. Docaravimab is an IgG2b monoclonal antibody directed against an epitope associated with antigenic site III, while Miromavimab is an IgG1 monoclonal antibody directed against antigenic site II. By binding to the virus at different sites, the antibodies neutralize rabies virus and help prevent viral infection of susceptible cells near the exposure site. The combination is administered by local infiltration into and around the wound and is used together with an appropriate rabies vaccination regimen rather than as a substitute for vaccination. The recommended dose of the combination is 40 IU/kg body weight. Docaravimab and Miromavimab are clinically important because they provide immediate passive antiviral protection during the early period after exposure, before vaccine-induced active immunity has fully developed.

Docaravimab and Miromavimab were developed as recombinant monoclonal-antibody alternatives to conventional rabies immunoglobulin for post-exposure prophylaxis. The antibodies recognize different non-overlapping antigenic sites on the rabies virus glycoprotein and were selected to provide complementary neutralizing activity. The World Health Organization's International Nonproprietary Names programme listed docaravimab and miromavimab as antiviral immunomodulatory monoclonal antibodies, and both were subsequently considered among rabies monoclonal antibodies for international public-health use. A Phase 3 randomized non-inferiority trial compared the combination with human rabies immunoglobulin in WHO category III exposures and found the monoclonal-antibody cocktail non-inferior according to the study's predefined immunogenicity endpoint, with no deaths or serious adverse events reported in the trial. In India, the Drug Controller General of India (DCGI) granted permission for manufacture and marketing in 2019 following evaluation of Phase 3 clinical data by the relevant Indian regulatory and expert committees. The available regulatory evidence identifies India as the principal market in which this combination received authorization; it is not presented as an FDA- or EMA-approved medicine.

Docaravimab and Miromavimab are indicated in India for post-exposure prophylaxis in individuals with suspected rabies exposure. The combination is intended for use as part of a complete rabies post-exposure prophylaxis programme and must be administered together with an appropriate rabies vaccine according to the applicable vaccination regimen. Its role is to provide immediate passive neutralizing antibodies at the site of exposure while the rabies vaccine stimulates the patient's own active immune response. It is particularly relevant following exposures requiring rabies immunoglobulin according to established clinical and public-health guidance, including appropriate category III animal exposures. The monoclonal-antibody cocktail is not intended to replace rabies vaccination and should not be used as a standalone long-term treatment for established clinical rabies.

Docaravimab and Miromavimab are administered by a healthcare professional through infiltration in and around the wound or wounds as soon as possible after exposure, together with rabies vaccination. The recommended dose of the combination is 40 IU/kg of body weight. Available formulations contain equal amounts of docaravimab and miromavimab and include different concentrations and vial volumes designed to provide the required dose according to body weight. The monoclonal-antibody cocktail is administered as a single post-exposure dose rather than as a repeated course. Rabies vaccine must be continued according to the applicable post-exposure vaccination schedule, such as an approved intramuscular or intradermal regimen. Thorough wound cleansing should also be performed promptly as part of rabies post-exposure management.

Common adverse effects reported with Docaravimab and Miromavimab are generally associated with the injection or local wound-infiltration procedure. These may include pain, tenderness, redness, or swelling at the administration site, as well as systemic symptoms such as fever, malaise, headache, or muscle aches. In post-marketing surveillance, local reactions such as pain and tenderness and systemic reactions such as fever, malaise, and myalgia have been reported. Most reported reactions have been manageable with appropriate medical observation and treatment when required. The frequency and severity of adverse effects can vary between individuals and may also be influenced by the underlying animal-bite injury and concomitant rabies vaccination.

Serious adverse reactions are uncommon but clinically important hypersensitivity reactions, including severe allergic reactions, should be considered with any monoclonal-antibody preparation. Patients should be observed appropriately after administration, particularly when there is a history of hypersensitivity to biological products or any component of the preparation. The combination should be used according to the approved indication and should not be administered as a substitute for rabies vaccination. Correct wound infiltration is important because the antibodies are intended to provide passive neutralization at the exposure site. Clinical studies of the combination have reported no deaths or serious adverse events in the Phase 3 trial, while subsequent surveillance has continued to evaluate its safety in real-world category III exposures.

Before administration, the healthcare professional should confirm the indication, assess the exposure and wounds, review any known hypersensitivity to monoclonal antibodies or product components, and ensure that rabies vaccination is arranged as part of the complete post-exposure regimen. Immediate and thorough wound washing remains an essential component of management and should not be replaced by antibody administration. Because Docaravimab and Miromavimab are administered locally and act by directly binding rabies virus rather than through conventional metabolic pathways, classic CYP-mediated drug interactions are not expected to be a major concern. Nevertheless, the combination should be used according to rabies post-exposure protocols, and administration should be coordinated with the rabies vaccine. Patients with extensive or multiple wounds require careful assessment to ensure appropriate infiltration of the calculated dose.

Prescribers and pharmacists should verify the patient's body weight, exposure category, wound locations, calculated antibody requirement, product concentration, and vaccination plan before administration. The complete calculated dose should be appropriately infiltrated in and around the exposure wounds according to the product instructions and clinical anatomy. Confirm that the patient also receives the recommended rabies vaccine because the monoclonal-antibody cocktail provides passive immunity and does not replace active immunization. Proper wound cleansing should be reinforced as an immediate first step. Healthcare professionals should monitor for local reactions and symptoms of hypersensitivity after administration and document the product, dose, administration site, and vaccination schedule. Pharmacists should also ensure correct storage and handling of the biological product and verify that the selected vial strength provides the required dose without confusing the concentration of the individual antibodies with the total antibody potency.